Topic Compilations

Topic Compilations

Each of our Topic Compilations includes a collection of features and news articles published in ASH Clinical News related to a specific hematologic disorder.

ECHELON-2: Brentuximab Vedotin Combination Outperforms CHOP for Peripheral T-Cell Lymphomas

Results from the phase III ECHELON-2 trial showed that brentuximab vedotin added to a combination of cyclophosphamide, doxorubicin, and prednisone (BV+CHP) nearly doubled progression-free...

Selinexor Induces Deep Responses in Refractory Multiple Myeloma

More than one-quarter of patients with refractory multiple myeloma (MM) responded to treatment with a combination of selinexor and low-dose dexamethasone, according to results...

Four Cycles as Effective as Six Cycles of Chemotherapy for Favorable-Risk DLBCL

While young patients with diffuse large B-cell lymphoma (DLBCL) are typically treated with six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), results from...

Luspatercept Reduces the Need for Transfusions in Patients With Beta Thalassemia and MDS

In two separate phase III trials presented at the 2018 ASH Annual Meeting, luspatercept, a first-in-class recombinant fusion protein, was found to be safe...

New Drug Approvals in Nonmalignant Hematology

In 2018, the U.S. Food and Drug Administration (FDA) set a record for the number of approvals for new therapies – or new indications...

Is a Longer Schedule of Decitabine More Effective Than a 5-Day Schedule in Older...

For older patients with treatment-naïve acute myeloid leukemia (AML), research has suggested that a 10-day treatment schedule of the hypomethylating agent decitabine is associated...
WIB_icon

Enasidenib Induces Molecular Remissions in IDH2-Mutated, Relapsed/Refractory AML

A first-in-human trial of patients with relapsed and/or refractory, IDH2-mutated acute myeloid leukemia (AML) found that the IDH2 inhibitor enasidenib was an effective salvage...

FDA Approves Gilteritinib for FLT3-Mutated AML

The oral FLT3/AXL inhibitor gilteritinib was approved by the FDA for the treatment of adult patients with FLT3-mutated, relapsed or refractory AML. The FDA...

First Biosimilar for Rituximab Gains Approval

The FDA approved rituximab-abbs, the first biosimilar of rituximab, for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma (NHL). This marks the...

Algorithm Built on Big Data Improves Prognostic Accuracy Over Existing MDS Models

Using machine learning, researchers were able to develop a prognostic model that predicted survival among patients with myelodysplastic syndromes (MDS) and was more accurate...
Advertisement

Current Issue

January 2019 Annual Meeting Edition

This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.